Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma

Authors

N. L. Bartlett, Washington University School of Medicine in St. Louis
A. Ghobadi, Washington University School of Medicine in St. Louis
et al

Journal

The New England Journal of Medicine

Publication Date

2017

Volume

377

Issue

26

Inclusive Pages

2531-2544

Document Type

Open Access Publication

DOI

10.1056/NEJMoa1707447

Rights and Permissions

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., . . . Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2531-2544. doi:10.1056/NEJMoa1707447. Copyright © 2017 Massachusetts Medical Society. http://www.nejm.org/doi/full/10.1056/NEJMoa1707447.

Recommended Citation

Bartlett, N. L.; Ghobadi, A.; and et al, "Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-Cell lymphoma." The New England Journal of Medicine. 377, 26. 2531-2544. (2017).
https://digitalcommons.wustl.edu/open_access_pubs/6487